Trial Profile

IVA-PEF

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 14 Oct 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ivabradine (Primary)
Indications Heart failure; Left ventricular dysfunction
Focus Therapeutic Use
Acronyms IVA-PEF

Most Recent Events

13 Oct 2022 According to UMIN record, Date of closure to data entry 8 Apr 2022, Date trial data considered complete 8 Apr 2022, Date analysis concluded 19 Apr 2022.
13 Oct 2022 Status changed from recruiting to completed.
11 Oct 2021 Planned End Date changed from 1 Dec 2022 to 30 Apr 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com